Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 94
Inclusion Criteria
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
- Ocular hypertension or glaucoma that requires treatment with medication
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
- Ocular hypertension or glaucoma that requires treatment with medication
Exclusion Criteria
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
Summary
- Conditions
- Glaucoma
- Ocular Hypertension
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
- Ocular hypertension or glaucoma that requires treatment with medication
- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
- Ocular hypertension or glaucoma that requires treatment with medication
Exclusion Criteria
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
- History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
Tracking Information
- NCT #
- NCT02097719
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Allergan
Get Well Soon